Chimaeric antigen receptor T-cell therapy for tumour immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Chimaeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer immunotherapy.
• CAR T-cell therapy targeting CD19 has demonstrated high efficacy in treating B-cell malignancies.

Purpose of the Study:

• To review the fundamental structure of CARs.
• To summarize reported tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) targeted by CAR T-cells.
• To present an overview of clinical trial outcomes, challenges, and future prospects of CAR T-cell therapies.

Main Methods:

• Literature review of existing studies on CAR T-cell therapy.
• Analysis of data from in vitro and in vivo experiments.
• Compilation of results from ongoing and completed clinical trials.

Main Results:

• CAR T-cell therapy is highly effective for B-cell malignancies, with CD19 being a primary target.
• Trials are exploring various TSAs/TAAs beyond CD19 for both hematologic and solid tumors.
• Two life-threatening side effects associated with CAR T-cell therapy have been identified.

Conclusions:

• CAR T-cell therapy holds immense promise for cancer treatment, with ongoing research focused on expanding its application.
• Future efforts are directed towards identifying novel cancer targets and developing strategies to enhance the safety of CAR T-cell therapy.
• Continued research in CAR T-cell therapy aims to improve efficacy and mitigate adverse events for broader patient benefit.